Logo image of FRTX

FRESH TRACKS THERAPEUTICS IN (FRTX) Stock Fundamental Analysis

NASDAQ:FRTX - Nasdaq - US10802T2042 - Common Stock - Currency: USD

0.79  -0.02 (-2.48%)

After market: 0.77 -0.02 (-2.53%)

Fundamental Rating

2

Taking everything into account, FRTX scores 2 out of 10 in our fundamental rating. FRTX was compared to 563 industry peers in the Biotechnology industry. FRTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. FRTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year FRTX has reported negative net income.
FRTX had a negative operating cash flow in the past year.
FRTX had negative earnings in each of the past 5 years.
FRTX had a negative operating cash flow in each of the past 5 years.
FRTX Yearly Net Income VS EBIT VS OCF VS FCFFRTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M -40M

1.2 Ratios

FRTX's Return On Assets of -68.63% is on the low side compared to the rest of the industry. FRTX is outperformed by 67.28% of its industry peers.
FRTX has a Return On Equity (-82.48%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -68.63%
ROE -82.48%
ROIC N/A
ROA(3y)-133.33%
ROA(5y)-101.24%
ROE(3y)-176.24%
ROE(5y)-148.19%
ROIC(3y)N/A
ROIC(5y)N/A
FRTX Yearly ROA, ROE, ROICFRTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for FRTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FRTX Yearly Profit, Operating, Gross MarginsFRTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -2K -4K -6K -8K -10K

More info and screens

6

2. Health

2.1 Basic Checks

FRTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, FRTX has more shares outstanding
There is no outstanding debt for FRTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
FRTX Yearly Shares OutstandingFRTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 500K 1M 1.5M 2M 2.5M
FRTX Yearly Total Debt VS Total AssetsFRTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -17.49, we must say that FRTX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of FRTX (-17.49) is worse than 88.81% of its industry peers.
FRTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -17.49
ROIC/WACCN/A
WACC10.98%
FRTX Yearly LT Debt VS Equity VS FCFFRTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M 60M

2.3 Liquidity

FRTX has a Current Ratio of 6.19. This indicates that FRTX is financially healthy and has no problem in meeting its short term obligations.
FRTX has a Current ratio of 6.19. This is comparable to the rest of the industry: FRTX outperforms 59.60% of its industry peers.
A Quick Ratio of 6.19 indicates that FRTX has no problem at all paying its short term obligations.
FRTX's Quick ratio of 6.19 is in line compared to the rest of the industry. FRTX outperforms 59.93% of its industry peers.
Industry RankSector Rank
Current Ratio 6.19
Quick Ratio 6.19
FRTX Yearly Current Assets VS Current LiabilitesFRTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 68.84% over the past year.
FRTX shows a strong growth in Revenue. In the last year, the Revenue has grown by 101.00%.
Measured over the past years, FRTX shows a very negative growth in Revenue. The Revenue has been decreasing by -12.87% on average per year.
EPS 1Y (TTM)68.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%115.46%
Revenue 1Y (TTM)101%
Revenue growth 3Y-4.31%
Revenue growth 5Y-12.87%
Sales Q2Q%1520.41%

3.2 Future

FRTX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.32% yearly.
The Revenue is expected to decrease by -8.37% on average over the next years.
EPS Next Y5.44%
EPS Next 2Y3.32%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-58.02%
Revenue Next 2Y-8.37%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
FRTX Yearly Revenue VS EstimatesFRTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
FRTX Yearly EPS VS EstimatesFRTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2020 2021 2022 2023 2024 -200 -400 -600

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FRTX. In the last year negative earnings were reported.
Also next year FRTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FRTX Price Earnings VS Forward Price EarningsFRTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FRTX Per share dataFRTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.32%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FRTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FRESH TRACKS THERAPEUTICS IN

NASDAQ:FRTX (12/18/2023, 8:00:00 PM)

After market: 0.77 -0.02 (-2.53%)

0.79

-0.02 (-2.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2023-11-13/amc
Earnings (Next)03-28 2024-03-28/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners42.16%
Ins Owner Change0%
Market Cap4.72M
Analysts82.86
Price Target4.59 (481.01%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-8.61%
Min Revenue beat(2)-90.2%
Max Revenue beat(2)72.98%
Revenue beat(4)1
Avg Revenue beat(4)-31.48%
Min Revenue beat(4)-98.04%
Max Revenue beat(4)72.98%
Revenue beat(8)3
Avg Revenue beat(8)-19.3%
Revenue beat(12)4
Avg Revenue beat(12)-10.85%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.47
P/FCF N/A
P/OCF N/A
P/B 0.43
P/tB 0.43
EV/EBITDA N/A
EPS(TTM)-2.67
EYN/A
EPS(NY)-6.91
Fwd EYN/A
FCF(TTM)-0.97
FCFYN/A
OCF(TTM)-0.97
OCFYN/A
SpS1.68
BVpS1.84
TBVpS1.84
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -68.63%
ROE -82.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-133.33%
ROA(5y)-101.24%
ROE(3y)-176.24%
ROE(5y)-148.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.77
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.19
Quick Ratio 6.19
Altman-Z -17.49
F-Score6
WACC10.98%
ROIC/WACCN/A
Cap/Depr(3y)188.89%
Cap/Depr(5y)125.33%
Cap/Sales(3y)3.94%
Cap/Sales(5y)2.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%115.46%
EPS Next Y5.44%
EPS Next 2Y3.32%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)101%
Revenue growth 3Y-4.31%
Revenue growth 5Y-12.87%
Sales Q2Q%1520.41%
Revenue Next Year-58.02%
Revenue Next 2Y-8.37%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y60.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y83.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y83.93%
OCF growth 3YN/A
OCF growth 5YN/A